Erratum To: Guidance for the Prevention of Bone Loss and Fractures in Postmenopausal Women Treated With Aromatase Inhibitors for Breast Cancer: An ESCEO Position Paper

Osteoporosis International - United Kingdom
doi 10.1007/s00198-012-1930-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Bone Loss and the Aromatase Inhibitors

British Journal of Cancer
Cancer ResearchOncology
2005English

Denosumab for the Prevention of Osteoporotic Fractures in Postmenopausal Women

Health Technology Assessment
MedicineHealth Policy
2011English

Anastrozole as Aromatase Inhibitor – New Approaches to Breast Cancer Treatment in Postmenopausal Women

Nowotwory
Cancer ResearchOncology
2019English

Effects of Steroidal and Nonsteroidal Aromatase Inhibitors on Markers of Bone Turnover in Healthy Postmenopausal Women

Breast Cancer Research
Cancer ResearchOncology
2007English

Once-Yearly Zoledronic Acid in the Prevention of Osteoporotic Bone Fractures in Postmenopausal Women

Clinical Interventions in Aging
MedicineGerontologyGeriatrics
2008English

RANKL/RANK: From Bone Loss to the Prevention of Breast Cancer

Open Biology
BiochemistryImmunologyGeneticsMolecular BiologyNeuroscience
2016English

Review of Hormone-Based Treatments in Postmenopausal Patients With Advanced Breast Cancer Focusing on Aromatase Inhibitors and Fulvestrant

ESMO Open
Cancer ResearchOncology
2016English

Prospective Characterization of Musculoskeletal Symptoms in Early Stage Breast Cancer Patients Treated With Aromatase Inhibitors

Breast Cancer Research and Treatment
Cancer ResearchOncology
2007English

Estrone Sulphate, FSH, and Testosterone Levels in Two Male Breast Cancer Patients Treated With Aromatase Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy